Purpose: To evaluate the effects of the orally administered thymic protein A on clinical blood parameters and the subjective symptoms common to patients with chronic fatigue and immune dysfunction syndrome (CFIDS). Materials and Methods: A novel immune modulator, thymic protein A, in oral formulation was tested in 23 CFIDS patients manifesting clinical symptoms of CFIDS and abnormal CD8+ subpopulations and interferon pathway-associated enzyme levels. Results: Sixteen of the 23 patients experienced normalization of immune function with a corresponding improvement in clinical symptoms of CFIDS. Conclusion: The data suggest that reinstitution of immune regulation with thymic protein A may ameliorate symptoms associated with CFIDS.
A Look at Infectious Agents as a Possible Causative Factor in Cardiovascular Disease: Part III
The link between infection and cardiovascular disease has been assessed by measuring the presence of antibodies against the pathogen. There are several mechanisms by which the immune response to a virus can result in immunopathology. Knowledge about molecular mimicry...
